Noninvasive Procedure Is Superior to Steroid Injection for Painful Knee Osteoarthritis
Article ID: 684470
Released: 2-Nov-2017 10:40 AM EDT
Source Newsroom: Wolters Kluwer Health: Lippincott Williams and Wilkins
Newswise — November 2, 2017 – For patients with osteoarthritis of the knee, a minimally invasive procedure called cooled radiofrequency ablation (CRFA) provides better pain reduction and functional improvement compared to steroid injection of the knee, concludes a study in Regional Anesthesia & Pain Medicine, published by Wolters Kluwer.
"This study demonstrates that CRFA is an effective long-term therapeutic option for managing pain, and improving physical function and quality of life, for patients suffering from painful knee osteoarthritis when compared with intra-articular steroid injection," according to the clinical trial report by Leonardo Kapural, MD, PhD, of the Center for Clinical Research, Winston-Salem, N.C., and colleagues.
Most Patients Get Lasting Relief of Knee Osteoarthritis Pain with CRFA
Knee osteoarthritis is a common and painful condition in older adults. Knee replacement surgery is an established option for patients with advanced osteoarthritis, but is not appropriate for all patients because of age or health status. Even patients who have knee replacement may have ongoing pain, despite a mechanically satisfactory prosthesis. Intra-articular (within the joint) steroid injection is commonly performed, but provides only short-term pain relief. In addition, steroids may have adverse effects on cartilage over time
Dr. Kapural and colleagues evaluated CRFA as an alternative to steroid injection in 151 patients with chronic pain from knee osteoarthritis. The patients had had knee pain for an average of about ten years, with many previous treatments. They were randomly assigned to undergo CRFA or steroid injection.
The noninvasive CRFA procedure uses radiofrequency energy to interrupt pain transmission by a specific nerve (genicular nerve) of the knee. Before the procedure, a local anesthetic nerve block is performed to confirm that numbing the genicular nerve reduces the patient's knee pain. Cooled radiofrequency ablation is performed on an outpatient basis, with local anesthesia and minimal sedation.
Patients undergoing CRFA had significant and lasting reduction in pain scores. From an initial pain score of about 7 on a 10-point scale, pain ratings at one month were about 3 in the CRFA group versus 4 in the steroid group.
With further follow-up, pain scores remained lower in the CRFA group while increasing toward the pre-treatment level in the steroid group. At six months, 74 percent of patients assigned to CRFA had at least a one-half reduction in pain scores, compared to 16 percent of those undergoing steroid injection.
Forty percent of patients in the CRFA group rated their knee function "satisfactory" at six months' follow-up, compared to just three percent of the steroid group. Ninety-one percent of the CRFA group felt their overall health had improved, compared to 24 percent in the steroid group.
Patients undergoing CRFA had greater reduction in the use of conventional, non-opioid pain medications. There was no significant difference in opioids, which were used by a minority of patients in both groups. There were no serious treatment-related adverse events in either group.
The results suggest that CRFA provides "clinically meaningful" pain reduction and functional improvement in patients with knee OA, with better and longer-lasting improvement than steroid injection. Dr. Kapural and colleagues plan longer follow-up to assess outcomes at one year and beyond. They note that pain may return as the treated nerve regenerates; if so, repeating the CRFA procedure is a "reasonable and sensible" option.
The authors note some limitations of their study, including the fact that the results weren't assessed in "blinded" fashion. They also suggest more focused studies to see if CRFA can reduce the need for opioid pain medications. Dr. Kapural and coauthors conclude, "Nonetheless, the findings of this study indicate that CRFA for genicular nerve ablation is superior to a single corticosteroid injection in osteoarthritic subjects for management of knee pain."
Click here to read “Prospective, Multicenter, Randomized, Crossover Clinical Trial Comparing the Safety and Effectiveness of Cooled Radiofrequency Ablation With Corticosteroid Injection in the Management of Knee Pain From Osteoarthritis.”
About Regional Anesthesia & Pain Medicine
Regional Anesthesia & Pain Medicine, official publication of the American Society of Regional Anesthesia and Pain Medicine, publishes 8 issues per year, focusing on high quality peer-reviewed scientific and clinical studies that advance the understanding and clinical application of regional anesthesia and procedural techniques for the treatment of the full spectrum of pain including perioperative anesthesia and analgesia, chronic pain, cancer pain, obstetric analgesia, pediatric analgesia, outcome studies, and complications.
About the American Society of Regional Anesthesia and Pain Medicine
The American Society of Regional Anesthesia and Pain Medicine (ASRA) is the premier organization that addresses the clinical and professional educational needs of physicians and scientists, assures excellence in patient care utilizing regional anesthesia and pain medicine, and investigates the scientific basis of the specialty. With nearly 6,000 members in 60 countries, ASRA is the largest organization of its kind dedicated to excellence and consistency in the practice of regional anesthesia and pain medicine. It is also the largest subspecialty organization in anesthesiology.
About Wolters Kluwer
Wolters Kluwer N.V. (AEX: WKL) is a global leader in information services and solutions for professionals in the health, tax and accounting, risk and compliance, finance and legal sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.
Wolters Kluwer reported 2016 annual revenues of €4.3 billion. The company, headquartered in Alphen aan den Rijn, the Netherlands, serves customers in over 180 countries, maintains operations in over 40 countries and employs 19,000 people worldwide.
Wolters Kluwer Health is a leading global provider of information and point of care solutions for the healthcare industry. For more information about our products and the organization, visit http://www.wolterskluwer.com/, follow @WKHealth or @Wolters_Kluwer on Twitter, like us on Facebook, follow us on LinkedIn, or follow WoltersKluwerComms on YouTube.